IRF-1 expression is essential for natural killer cells to suppress metastasis

Cancer Research

Volumn 71, Issue 20, 2011, Pages 6410-6418

  Ksienzyk, Antje ^a   Neumann, Berit ^a   Nandakumar, Ramya ^a   Finsterbusch, Katja ^a   Grashoff, Martina ^a   Zawatzky, Rainer ^b   Bernhardt, Günter ^c   Hauser, Hansjörg ^a   Kröger, Andrea ^a  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD69 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; CXCL11 CHEMOKINE; DEATH RECEPTOR 5; GAMMA INTERFERON; GRANZYME B; HEMAGGLUTININ; INTERFERON; INTERFERON REGULATORY FACTOR 1; NATURAL KILLER CELL RECEPTOR NKG2D; PERFORIN; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DOWN REGULATION; IMMUNOSURVEILLANCE; LUNG METASTASIS; METASTASIS POTENTIAL; MOUSE; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR GROWTH;

ANIMALS; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CARCINOMA; CELL LINE, TUMOR; COLONIC NEOPLASMS; GRANZYMES; INTERFERON REGULATORY FACTOR-1; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; PERFORIN; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, VIRUS; UP-REGULATION;

EID: 80054041125     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-1565     Document Type: Article

References (42)

1. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006;6:836-48. (Pubitemid 44631652)
2. Voskoboinik I, Smyth MJ, Trapani JA. Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol 2006;6:940-52. (Pubitemid 44851736)
3. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Old LJ, Aguet M, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 1998;95:7556-61. (Pubitemid 28293291)
4. Bromberg JF, Horvath CM, Wen Z, Schreiber RD, Darnell JE Jr. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci U S A 1996;93:7673-8. (Pubitemid 26277095)
5. Xu X, Fu XY, Plate J, Chong AS. IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res 1998;58:2832-7. (Pubitemid 28311915)
6. Luster AD, Leder P. IP-10, a-C-X-C-chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med 1993;178:1057-65. (Pubitemid 23260444)
7. Kröger A, Koster M, Schroeder K, Hauser H, Mueller PP. Activities of IRF-1. J Interferon Cytokine Res 2002;22:5-14. (Pubitemid 34161278)
8. Taki S, Sato T, Ogasawara K, Fukuda T, Sato N, Hida S, et al. Multistage regulation of Th1-type immune responses by the transcription factor IRF-1. Immunity 1997;6:673-9. (Pubitemid 27305730)
9. Duncan GS, Mittrucker HW, Kagi D, Matsuyama T, Mak TW. The transcription factor interferon regulatory factor-1 is essential for natural killer cell function in vivo. J Exp Med 1996;184:2043-8. (Pubitemid 26404496)
10. Harada H, Kitagawa M, Tanaka N, Yamamoto H, Harada M, Ishikara M, et al. Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. Science 1993;259:971-4. (Pubitemid 23080666)
11. Kröger A, Ortmann D, Krohne TU, Mohr L, Blum HE, Hauser H, et al. Growth suppression of the hepatocellular carcinoma cell line Hepa1-6 by an activatable interferon regulatory factor-1 in mice. Cancer Res 2001;61:2609-17. (Pubitemid 32685846)
12. Kröger A, Stirnweiss A, Pulverer JE, Klages K, Grashoff M, Reimann J, et al. Tumor suppression by IFN regulatory factor-1 is mediated by transcriptional down-regulation of cyclin D1. Cancer Res 2007;67:2972-81. (Pubitemid 46724833)
13. Nozawa H, Oda E, Nakao K, Ishihara M, Ueda S, Yokochi T, et al. Loss of transcription factor IRF-1 affects tumor susceptibility in mice carrying the Ha-ras transgene or nullizygosity for p53. Genes Dev 1999;13:1240-5. (Pubitemid 29250191)
14. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, et al. Functional role of type I and type II interferons in antiviral defense. Science 1994;264:1918-21. (Pubitemid 24245635)
15. Scherr M, Battmer K, Ganser A, Eder M. Modulation of gene expression by lentiviral-mediated delivery of small interfering RNA. Cell Cycle 2003;2:251-7.
16. Kröger A, Dallugge A, Kirchhoff S, Hauser H. IRF-1 reverts the transformed phenotype of oncogenically transformed cells in vitro and in vivo. Oncogene 2003;22:1045-56. (Pubitemid 36313148)
17. Yim JH, Wu SJ, Casey MJ, Norton JA, Doherty GM. IFN regulatory factor-1 gene transfer into an aggressive, nonimmunogenic sarcoma suppresses the malignant phenotype and enhances immunogenicity in syngeneic mice. J Immunol 1997;158:1284-92. (Pubitemid 127469953)
18. Swann JB, Hayakawa Y, Zerafa N, Sheehan CF, Scott B, Schreiber RD, et al. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol 2007;178:7540-9. (Pubitemid 46898022)
19. Liu J, Xiang Z, Ma X. Role of IFN regulatory factor-1 and IL-12 in immunological resistance to pathogenesis of N-methyl-N-nitrosourea-induced T lymphoma. J Immunol 2004;173:1184-93. (Pubitemid 38924295)
20. Hillman GG, Younes E, Visscher D, Hamazavi F, Kim S, Lam JS, et al. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4. Clin Cancer Res 1997;3:1799-806. (Pubitemid 27444720)
21. Tanaka N, Ishihara M, Taniguchi T. Suppression of c-myc or fosB-induced cell transformation by the transcription factor IRF-1. Cancer Lett 1994;83:191-6. (Pubitemid 24253537)
22. Hanna N, Burton RC. Definitive evidence that natural killer (NK) cells inhibit experimental tumor metastases in vivo. J Immunol 1981;127:1754-8. (Pubitemid 11023139)
23. Gazit R, Gruda R, Elboim M, Arnon TI, Katz G, Achdout H, et al. Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1. Nat Immunol 2006;7:517-23.
24. Wittmann M, Purwar R, Hartmann C, Gutzmer R, Werfel T. Human keratinocytes respond to interleukin-18: implication for the course of chronic inflammatory skin diseases. J Invest Dermatol 2005;124:1225-33. (Pubitemid 40847410)
25. Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005;6:722-9. (Pubitemid 41716746)
26. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 1999;17:189-220. (Pubitemid 29241123)
27. Miyamoto M, Fujita T, Kimura Y, Maruyama M, Harada H, Sudo Y, et al. Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-beta gene regulatory elements. Cell 1988;54:903-13.
28. Arase H, Arase N, Saito T. Fas-mediated cytotoxicity by freshly isolated natural killer cells. J Exp Med 1995;181:1235-8.
29. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82. (Pubitemid 26091143)
30. Kägi D, Ledermann B, Bürki K, Seiler P, Odermatt B, Olsen KJ, et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994;369:31-7. (Pubitemid 24144352)
31. Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, Kayagaki N, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 2001;193:661-70. (Pubitemid 32524460)
32. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol 2008;9:503-10. (Pubitemid 351560519)
33. Long EO. Regulation of immune responses through inhibitory receptors. Annu Rev Immunol 1999;17:875-904. (Pubitemid 29241142)
34. Gasser S, Raulet DH. Activation and self-tolerance of natural killer cells. Immunol Rev 2006;214:130-42. (Pubitemid 44707907)
35. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001;413:165-71. (Pubitemid 32867877)
36. Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat Rev Immunol 2001;1:41-9. (Pubitemid 33741974)
37. El-Sherbiny YM, Meade JL, Holmes TD, McGonagle D, Mackie SL, Morgan AW, et al. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res 2007;67:8444-9. (Pubitemid 47437416)
38. Iguchi-Manaka A, Kai H, Yamashita Y, Shibata K, Tahara-Hanaoka S, Honda S, et al. Accelerated tumor growth in mice deficient in DNAM-1 receptor. J Exp Med 2008;205:2959-64.
39. Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 2003;198:557-67. (Pubitemid 37040390)
40. Pende D, Bottino C, Castriconi R, Cantoni C, Marcenaro S, Rivera P, et al. PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. Mol Immunol 2005;42:463-9. (Pubitemid 39655955)
41. Gilfillan S, Chan CJ, Cella M, Haynes NM, Rapaport AS, Boles KS, et al. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med 2008;205:2965-73.
42. Chan CJ, Andrews DM, McLaughlin NM, Yagita H, Gilfillan S, Collona M, et al. DNAM-11/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. J Immunol 2010;184:902-11.